Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CB1 receptor antagonists reported by sanofi-aventis for the treatment of diabetes

Oct. 19, 2009

ZyStor Therapeutics cleared by FDA to start phase I trial of ZC-701 in Pompe disease

Oct. 19, 2009

Protalix presents topline results from phase III Uplyso trial

Oct. 16, 2009

Bristol-Myers Squibb claims 11beta-HSD1 inhibitors for diabetes and other conditions

Oct. 16, 2009

DURATION-1 and -2 studies detail effects of once-weekly exenatide in type 2 diabetes

Oct. 16, 2009

Fatostatin inhibits SREBP activation and reduces glucose levels and body weight in obese mice

Oct. 16, 2009

Depomed reports results of phase III trials of Serada for menopausal hot flashes

Oct. 15, 2009

Myriad identifies IND candidate targeting IKK epsilon

Oct. 15, 2009

BioMimetic Therapeutics presents topline data from its Augment Bone Graft trial

Oct. 15, 2009

Clinical data support safety and efficacy of S-equol in postmenopausal women

Oct. 15, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...